Kallyope News and Activities
Presence
Kallyope develops biotechnology therapies based on gut-brain biology. Its products and services include drug discovery and clinical development for pharmaceutical partners and patients with metabolic, neurological, and gastrointestinal conditions.
Kallyope products and services overview:
- Drug discovery
- Clinical development
- Metabolic therapies
- Neurology therapies
- Gastrointestinal therapies
- Research partnerships
Revenue: ~$10 million
Employees: 140
Headquarters: New York, United States (USA)
Kallyope is one of the...
Executives
View the org chart displaying its 24 main executives
Most searched biographies at Kallyope
Create your alert
to follow the executive moves at Kallyope.
Biotechnology
Kallyope has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
- NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
- Rallybio and Avenzo Therapeutics have announced they will merge (posted on June 1 2026)..
Popular contacts in Biotechnology
News
Press releases by Kallyope
Social media about Kallyope
- Kallyope on Wikipedia, Google News & Yahoo Finance
- Kallyope on LinkedIn, X (Twitter) & YouTube
